Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

A new meta-analysis of 174 randomized controlled trials on “carbohydrate-restricted diets” found consistent benefits for body composition, blood pressure, inflammation, and more. But instead of highlighting the metabolic benefits, most of the headlines focused almost entirely on a small bump in LDL. In this video, Bret Scher, MD breaks... show more

Metabolic Mind

22,255 subscribers

15,690 views • 8 months ago •via X (Twitter)

Health & Wellness Education Science & Technology

Anya Rossi• Live Now

Private livecam show

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

Why is Low-Carb Science so Freakin' Confusing? 🍟 **Give me 86 sec... Watch this trailer (🔊 on). Brief overview: There is terrible publication and media bias against carbohydrate-restricted and ketogenic diets that ranges from lowered publication standards to distorted headlines to full out lies authorized by peer review. In the full video, I break down and take down how recent and past major nutrition studies distort the data and mislead the public and patients who could benefit from therapeutic carbohydrate restriction. Link in comment 🔗👇 cc Dave Feldman Jan Ellison Baszucki Benjamin Bikman Andrew Koutnik, Ph.D. Metabolic Mind Coalition for Metabolic Health Bret Scher, MD Ken D Berry MD Austin Dudzinski, PharmD, BCACP Adrian Soto-Mota Dr. David Ludwig Dr David Unwin Eric Rodgers

Why is Low-Carb Science so Freakin' Confusing? 🍟 **Give me 86 sec... Watch this trailer (🔊 on). Brief overview: There is terrible publication and media bias against carbohydrate-restricted and ketogenic diets that ranges from lowered publication standards to distorted headlines to full out lies authorized by peer review. In the full video, I break down and take down how recent and past major nutrition studies distort the data and mislead the public and patients who could benefit from therapeutic carbohydrate restriction. Link in comment 🔗👇 cc Dave Feldman Jan Ellison Baszucki Benjamin Bikman Andrew Koutnik, Ph.D. Metabolic Mind Coalition for Metabolic Health Bret Scher, MD Ken D Berry MD Austin Dudzinski, PharmD, BCACP Adrian Soto-Mota Dr. David Ludwig Dr David Unwin Eric Rodgers

Nick Norwitz MD PhD

13,459 views • 10 months ago

Ketogenic diets in the ICU? The research is beginning to explore it. In a randomized controlled trial of 40 patients with sepsis, investigators tested a medically supervised ketogenic diet during critical illness. All patients in the ketogenic group achieved stable nutritional ketosis, with no serious adverse events attributed to the intervention. After day four, none of the ketogenic patients required insulin — compared to 35–60% of patients in the control group on any given day. The ketogenic group also experienced: • More ventilator-free days • More vasopressor-free days • More dialysis-free days • More ICU-free days Researchers observed signals consistent with reduced immune dysregulation and lower inflammatory signaling — a meaningful finding in a condition defined by metabolic chaos and systemic inflammation. This was a small, early-phase trial. It does not establish standard of care. But it adds to a growing body of evidence that metabolic therapy may have applications beyond chronic disease — including critical care. Check out the link below with details on how to access 150+ research summaries on metabolic health and therapy in our new Ketogenic Metabolic Therapy eBook!

Ketogenic diets in the ICU? The research is beginning to explore it. In a randomized controlled trial of 40 patients with sepsis, investigators tested a medically supervised ketogenic diet during critical illness. All patients in the ketogenic group achieved stable nutritional ketosis, with no serious adverse events attributed to the intervention. After day four, none of the ketogenic patients required insulin — compared to 35–60% of patients in the control group on any given day. The ketogenic group also experienced: • More ventilator-free days • More vasopressor-free days • More dialysis-free days • More ICU-free days Researchers observed signals consistent with reduced immune dysregulation and lower inflammatory signaling — a meaningful finding in a condition defined by metabolic chaos and systemic inflammation. This was a small, early-phase trial. It does not establish standard of care. But it adds to a growing body of evidence that metabolic therapy may have applications beyond chronic disease — including critical care. Check out the link below with details on how to access 150+ research summaries on metabolic health and therapy in our new Ketogenic Metabolic Therapy eBook!

Metabolic Health Summit

41,772 views • 6 months ago

A new meta-analysis published in JAMA Psychiatry examined 50 different keto studies, totaling over 40,000 participants, that included depression and anxiety outcomes. The results? Modest improvement in depression symptoms across different populations and diagnoses in both controlled and real-world scenarios Greater symptom improvement was observed in trials that included ketone monitoring. A larger effect was seen in “very low carbohydrate” diets compared to just “low carbohydrate” diets. Improvements in anxiety were also observed in most studies, but with less consistency than depressive symptoms. In this video, @bretschermd breaks down findings from this study and what the results mean for psychiatry.

A new meta-analysis published in JAMA Psychiatry examined 50 different keto studies, totaling over 40,000 participants, that included depression and anxiety outcomes. The results? Modest improvement in depression symptoms across different populations and diagnoses in both controlled and real-world scenarios Greater symptom improvement was observed in trials that included ketone monitoring. A larger effect was seen in “very low carbohydrate” diets compared to just “low carbohydrate” diets. Improvements in anxiety were also observed in most studies, but with less consistency than depressive symptoms. In this video, @bretschermd breaks down findings from this study and what the results mean for psychiatry.

Metabolic Mind

12,662 views • 8 months ago

Exercise can lower your blood pressure as effectively as medication A meta-analysis of randomized controlled trials found that 20-60 minutes of moderate to vigorous activity, 3-4 days a week, over just 6 weeks, can yield antihypertensive effects comparable to drugs The key is effort and consistency—no shortcuts here And if you’re willing to put in the work, the benefits of exercise go far beyond just lowering your blood pressure

Exercise can lower your blood pressure as effectively as medication A meta-analysis of randomized controlled trials found that 20-60 minutes of moderate to vigorous activity, 3-4 days a week, over just 6 weeks, can yield antihypertensive effects comparable to drugs The key is effort and consistency—no shortcuts here And if you’re willing to put in the work, the benefits of exercise go far beyond just lowering your blood pressure

FoundMyFitness Clips

33,856 views • 1 year ago

Ashwagandha is the most powerful adaptogen on the planet. A 2025 meta-analysis of RCTs found it crushes the stress hormone cortisol, while other trials show testosterone climbing up to 5x more than a placebo in just 8 weeks. Here are all its benefits (and how to use it):🧵

Ashwagandha is the most powerful adaptogen on the planet. A 2025 meta-analysis of RCTs found it crushes the stress hormone cortisol, while other trials show testosterone climbing up to 5x more than a placebo in just 8 weeks. Here are all its benefits (and how to use it):🧵

Ábris Babicz | The Demi Cycle Protocol 🧬

79,250 views • 1 month ago

Ashwagandha is the most powerful adaptogen on the planet. A 2025 meta-analysis of RCTs found it crushes the stress hormone cortisol, while other trials show testosterone climbing up to 5x more than a placebo in just 8 weeks. Here are all its benefits (and how to use it):🧵

Ashwagandha is the most powerful adaptogen on the planet. A 2025 meta-analysis of RCTs found it crushes the stress hormone cortisol, while other trials show testosterone climbing up to 5x more than a placebo in just 8 weeks. Here are all its benefits (and how to use it):🧵

Ábris Babicz | The Demi Cycle Protocol 🧬

161,896 views • 2 months ago

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

What if We're Using GLP-1 Medications All Wrong? Drugs like Ozempic, Wegovy, and Mounjaro are transforming the landscape of medical weight loss, but could their side effects be a sign that we’re not harnessing their full therapeutic potential? In this eye-opening conversation, Dr. Ben Bikman (Benjamin Bikman), metabolic health researcher and professor at BYU, joins Dr. Bret Scher (Bret Scher, MD) to explore a powerful new framework: using GLP-1 medications at low doses and for short durations to help curb carbohydrate cravings, break addictive eating cycles, and support long-term metabolic health. Rather than prescribing high doses indefinitely, Dr. Bikman proposes a more targeted approach: - Microdosing GLP-1s to enhance satiety and reduce cravings for processed carbs - Using the medication as a temporary metabolic tool to support transitions to lower-carb diets - Reducing long-term risks such as muscle loss, mood changes, and diminishing effectiveness - Emphasizing the importance of habit change, insulin regulation, and muscle preservation This conversation reimagines GLP-1s not as a lifelong solution, but as a catalyst for sustainable, low-insulin lifestyles, aligned with ketogenic and metabolic therapies. 📌 Could a 90-day microdosing protocol replace years of medication? Learn how this metabolic-first strategy could empower patients to reclaim their health, without becoming dependent on medication for life. #GLP1 #Ozempic #Wegovy #Mounjaro #BenBikman #MetabolicHealth #Microdosing #InsulinResistance #LowCarbDiet #KetogenicTherapy #MedicalWeightLoss #BretScher #MetabolicMind Expert Featured: Dr. Benjamin Bikman Benjamin Bikman Papers/Articles Mentioned: Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at Timestamps: 0:00 - What if we’re using GLP-1s all wrong? 1:40 - Dr. Benjamin Bikman’s interest in metabolic health and GLP-1s 3:20 - Unexpected side effect of GLP-1s 5:26 - Are GLP-1s actually beneficial? 10:55 - The difference between “weight loss” and metabolic health 15:10 - The role of cravings and satiety signals 19:58 - Dr. Bikman’s ideal use of GLP-1s 24:14 - “Self-discipline in a syringe” 25:11 - Are all weight loss interventions beneficial? 27:20- New studies examining microdosing GLP-1s 32:12 - Learn more about Dr. Bikman

Metabolic Mind

20,561 views • 1 year ago

How can doctors, psychiatrists, and other health practitioners implement keto for serious mental illnesses like schizophrenia, bipolar disorder, and depression? In this short interview, Bret Scher, MD sits down with Dr. Georgia Ede to discuss a newly published Delphi consensus paper in Frontiers in Nutrition, authored by eight experienced clinicians and researchers to establish best practices for the use of ketogenic metabolic therapy (KMT) in serious mental illnesses. 📚 Read the Paper: Published in Frontiers in Nutrition: Special shoutout to the 8 authors of this paper which include: Georgia Ede MD, Dr. Matthew Bernstein, Lori Calabrese MD, Iain Campbell, Ph.D., Nicole Laurent, LMHC, Chris Palmer, MD, Shebani Sethi, MD, and Beth Zupec-KANIA, RDN, CD

How can doctors, psychiatrists, and other health practitioners implement keto for serious mental illnesses like schizophrenia, bipolar disorder, and depression? In this short interview, Bret Scher, MD sits down with Dr. Georgia Ede to discuss a newly published Delphi consensus paper in Frontiers in Nutrition, authored by eight experienced clinicians and researchers to establish best practices for the use of ketogenic metabolic therapy (KMT) in serious mental illnesses. 📚 Read the Paper: Published in Frontiers in Nutrition: Special shoutout to the 8 authors of this paper which include: Georgia Ede MD, Dr. Matthew Bernstein, Lori Calabrese MD, Iain Campbell, Ph.D., Nicole Laurent, LMHC, Chris Palmer, MD, Shebani Sethi, MD, and Beth Zupec-KANIA, RDN, CD

Metabolic Mind

134,142 views • 5 months ago

🚨BIG NEWS: $50M Investment to End America's Health Crisis!🚨 🔬I'm Andrew Koutnik, PhD in Nutrition, Metabolism & Diabetes—and a patient living with an irreversible chronic metabolic disease. Thrilled to advise the NEW Coalition for Metabolic Health, LAUNCHED to REVERSE our chronic disease epidemic! Our 4 BOLD objectives: 1⃣Push policy shifts for science-based nutrition guidelines, research, screenings & insurance. 2⃣Fund unbiased research to empower docs & public with real metabolic insights. 3⃣Educate providers, policymakers & YOU on metabolism's power to prevent/reverse disease. 4⃣Incorporate therapeutic nutrition in everyday care via key partnerships. 👉Join the revolution: #MetabolicHealth #ReverseChronicDisease Metabolic Mind Jan Ellison Baszucki Bret Scher, MD Dr. David Ludwig Dominic D'Agostino Benjamin Bikman DoctorTro

🚨BIG NEWS: $50M Investment to End America's Health Crisis!🚨 🔬I'm Andrew Koutnik, PhD in Nutrition, Metabolism & Diabetes—and a patient living with an irreversible chronic metabolic disease. Thrilled to advise the NEW Coalition for Metabolic Health, LAUNCHED to REVERSE our chronic disease epidemic! Our 4 BOLD objectives: 1⃣Push policy shifts for science-based nutrition guidelines, research, screenings & insurance. 2⃣Fund unbiased research to empower docs & public with real metabolic insights. 3⃣Educate providers, policymakers & YOU on metabolism's power to prevent/reverse disease. 4⃣Incorporate therapeutic nutrition in everyday care via key partnerships. 👉Join the revolution: #MetabolicHealth #ReverseChronicDisease Metabolic Mind Jan Ellison Baszucki Bret Scher, MD Dr. David Ludwig Dominic D'Agostino Benjamin Bikman DoctorTro

Andrew Koutnik, Ph.D.

29,638 views • 11 months ago

There’s been a lot of buzz—and confusion—about the new Keto-CTA study, examining plaque progression in Lean Mass Hyper-Responders (LMHRs). Much of the social media debate has centered on whether high LDL on keto is safe or dangerous, driven largely by how to interpret the supplemental table comparing this study to others on LDL and plaque progression. In this episode of the Metabolic Mind Podcast, we sit down with Dr. Matthew Budoff, a world-renowned cardiologist, cardiac CT researcher, and the study's lead investigator, to discuss the the supplemental table, what the plaque markers mean, and how this fits into the discussion of high- vs -low-risk plaque progression. In this episode, we cover: ✅ What PAV (Percent Atheroma Volume) is, what it actually measures, and why it matters ✅ Why a 50% increase in plaque may sound scary, but can be deceiving ✅ The difference between “treatment-naive” and “treated” participants ✅ What the Miami Heart Study comparison reveals about keto, LDL, and plaque ✅ Why LDL alone may not tell the whole story about heart disease risk ✅ How some high-risk individuals may still benefit from statins and other therapies This study doesn’t answer whether keto causes heart disease or not. Instead, it shows that high LDL on a ketogenic diet is not a reliable predictor of plaque progression across all individuals. What is predictive? The presence of existing plaque. 💡 Key takeaway: Relying on surrogate markers of heart disease, like LDL and ApoB, is not the best way to assess heart disease risk in all populations. If you're concerned about how elevated LDL may be affecting your heart health, the best next step is to speak with your doctor about cardiac imaging to directly assess plaque and gain a clearer picture of your individual risk. Expert Featured: - Dr. Matthew Budoff - X: - Resources Mentioned: Plaque Begets Plaque, ApoB Does Not CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at

There’s been a lot of buzz—and confusion—about the new Keto-CTA study, examining plaque progression in Lean Mass Hyper-Responders (LMHRs). Much of the social media debate has centered on whether high LDL on keto is safe or dangerous, driven largely by how to interpret the supplemental table comparing this study to others on LDL and plaque progression. In this episode of the Metabolic Mind Podcast, we sit down with Dr. Matthew Budoff, a world-renowned cardiologist, cardiac CT researcher, and the study's lead investigator, to discuss the the supplemental table, what the plaque markers mean, and how this fits into the discussion of high- vs -low-risk plaque progression. In this episode, we cover: ✅ What PAV (Percent Atheroma Volume) is, what it actually measures, and why it matters ✅ Why a 50% increase in plaque may sound scary, but can be deceiving ✅ The difference between “treatment-naive” and “treated” participants ✅ What the Miami Heart Study comparison reveals about keto, LDL, and plaque ✅ Why LDL alone may not tell the whole story about heart disease risk ✅ How some high-risk individuals may still benefit from statins and other therapies This study doesn’t answer whether keto causes heart disease or not. Instead, it shows that high LDL on a ketogenic diet is not a reliable predictor of plaque progression across all individuals. What is predictive? The presence of existing plaque. 💡 Key takeaway: Relying on surrogate markers of heart disease, like LDL and ApoB, is not the best way to assess heart disease risk in all populations. If you're concerned about how elevated LDL may be affecting your heart health, the best next step is to speak with your doctor about cardiac imaging to directly assess plaque and gain a clearer picture of your individual risk. Expert Featured: - Dr. Matthew Budoff - X: - Resources Mentioned: Plaque Begets Plaque, ApoB Does Not CMEs Mentioned: Managing Major Mental Illness with Dietary Change: The New Science of Hope Brain Energy: The Metabolic Theory of Mental Illness Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry. Learn more about metabolic psychiatry and find helpful resources at

Metabolic Mind

98,147 views • 1 year ago

THE GREAT PEPTIDE DEBATE: FULL DISCUSSION Peptide bear Martin Shkreli squared off against peptide bull Max Marchione today in a back and forth on retatrutide, BPC-157, randomized controlled trials, the FDA, the pharmaceutical industry, and more. 00:00 Opening arguments 06:08 Martin on the downsides of retatrutide 10:24 Back and forth on BPC-157 14:41 Randomized controlled trials — issues and benefits 19:19 Max on the potential of Thymosin Alpha-1 23:21 Martin on why peptides should be controlled substances 26:07 The FDA's strengths and weaknesses 29:05 Closing arguments

THE GREAT PEPTIDE DEBATE: FULL DISCUSSION Peptide bear Martin Shkreli squared off against peptide bull Max Marchione today in a back and forth on retatrutide, BPC-157, randomized controlled trials, the FDA, the pharmaceutical industry, and more. 00:00 Opening arguments 06:08 Martin on the downsides of retatrutide 10:24 Back and forth on BPC-157 14:41 Randomized controlled trials — issues and benefits 19:19 Max on the potential of Thymosin Alpha-1 23:21 Martin on why peptides should be controlled substances 26:07 The FDA's strengths and weaknesses 29:05 Closing arguments

TBPN

174,214 views • 4 months ago

Megyn Kelly’s doctor told her statins should be in the drinking water. Her hormones doctor said absolutely not. So she asked Dr. Paul Saladino for the truth. His take: Cholesterol is essential for brain and hormone health. The real issue isn’t your LDL number in isolation, it’s your overall metabolic health. Even “normal” cholesterol can hide risk if fasting insulin, thyroid, or A1C is off. A 2025 study from The Lundquist Institute (KETO-CTA trial) found that in metabolically healthy people, high LDL cholesterol showed no significant increase in plaque buildup or cardiovascular risk. Metabolic health appears to matter far more than LDL levels alone. What’s your take, are we over-fearing cholesterol and under-focusing on real metabolic health?

Megyn Kelly’s doctor told her statins should be in the drinking water. Her hormones doctor said absolutely not. So she asked Dr. Paul Saladino for the truth. His take: Cholesterol is essential for brain and hormone health. The real issue isn’t your LDL number in isolation, it’s your overall metabolic health. Even “normal” cholesterol can hide risk if fasting insulin, thyroid, or A1C is off. A 2025 study from The Lundquist Institute (KETO-CTA trial) found that in metabolically healthy people, high LDL cholesterol showed no significant increase in plaque buildup or cardiovascular risk. Metabolic health appears to matter far more than LDL levels alone. What’s your take, are we over-fearing cholesterol and under-focusing on real metabolic health?

Camus

316,726 views • 2 months ago

Dr. Aseem Malhotra on the Root Cause of Chronic Disease & the Coming Shift in Dietary Guidelines For decades, the war on cholesterol & saturated fat has been a catastrophic public health failure. In 1977 (US) & 1981 (UK), dietary guidelines demonized natural fats—pushing people toward sugar & refined carbs. The result? A metabolic health crisis. Today, only 7% of American adults have optimal metabolic health. The evidence is clear: misguided dietary advice fueled the chronic disease pandemic. Dr. Aseem Malhotra has long argued this—from his BMJ exposé in 2013 (which faced fierce backlash) to his clinical work reversing metabolic syndrome in patients. The solution? Eat real food. Ditch ultra-processed junk. Prioritize metabolic health. For most, a low-carb diet is the fastest, most effective way to improve blood sugar, triglycerides, HDL, & more. The good news? Change is coming. Behind the scenes, Dr. Malhotra & other experts are working to reshape guidelines—potentially splitting recommendations for those with/without metabolic dysfunction. The message will be simple: Real food first. No more industry-driven pseudoscience. A long-overdue shift is on the horizon. And for those who’ve fought for truth in nutrition, it’ll be a monumental victory.

Dr. Aseem Malhotra on the Root Cause of Chronic Disease & the Coming Shift in Dietary Guidelines For decades, the war on cholesterol & saturated fat has been a catastrophic public health failure. In 1977 (US) & 1981 (UK), dietary guidelines demonized natural fats—pushing people toward sugar & refined carbs. The result? A metabolic health crisis. Today, only 7% of American adults have optimal metabolic health. The evidence is clear: misguided dietary advice fueled the chronic disease pandemic. Dr. Aseem Malhotra has long argued this—from his BMJ exposé in 2013 (which faced fierce backlash) to his clinical work reversing metabolic syndrome in patients. The solution? Eat real food. Ditch ultra-processed junk. Prioritize metabolic health. For most, a low-carb diet is the fastest, most effective way to improve blood sugar, triglycerides, HDL, & more. The good news? Change is coming. Behind the scenes, Dr. Malhotra & other experts are working to reshape guidelines—potentially splitting recommendations for those with/without metabolic dysfunction. The message will be simple: Real food first. No more industry-driven pseudoscience. A long-overdue shift is on the horizon. And for those who’ve fought for truth in nutrition, it’ll be a monumental victory.

Camus

25,765 views • 1 year ago

A brand new peer reviewed human study just revealed something huge. goBHB did more than provide clean energy. It helped subjects keep their lean muscle, lose fat, and maintain their metabolic rate even while eating fewer calories. This is the holy grail for anyone who wants to cut without losing size or strength. In this video, I break down the study results and explains why goBHB may be one of the most important ingredients for lifters, athletes, and anyone trying to improve their body composition. Learn how goBHB helped participants: • Preserve lean muscle during an eight week calorie deficit • Lose fat while improving their lean to fat mass ratio • Maintain resting metabolic rate instead of slowing down • Stay energized and perform better while dieting • Support metabolic and cardiovascular health with a clean safety profile If you want better cuts, stronger training sessions, and a real edge during calorie restriction, this study shows why goBHB belongs in your stack.

Marc Lobliner - IFBB Pro

128,667 views • 9 months ago